

PORTOLA PHARMACEUTICALS INC

Form S-8

March 02, 2015

As filed with the Securities and Exchange Commission on March 2, 2015

Registration No. 333-

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

Portola Pharmaceuticals, Inc.

(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction of
Incorporation or organization)

270 E. Grand Avenue

20-0216859
(I.R.S. Employer
Identification No.)

South San Francisco, California 94080

(650) 246-7300

(Address of principal executive offices) (Zip code)

Portola Pharmaceuticals, Inc. 2013 Equity Incentive Plan

(Full title of the plan)

William Lis

Chief Executive Officer

Portola Pharmaceuticals, Inc.

270 E. Grand Avenue

South San Francisco, California 94080

(650) 246-7300

(Name and address of agent for service) (Telephone number, including area code, of agent for service)

Copies to:

Kenneth L. Guernsey

Sally A. Kay

Cooley LLP

101 California Street, 5th Floor

San Francisco, CA 94111

(415) 693-2000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer
 Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company

CALCULATION OF REGISTRATION FEE

Title of Securities to be Registered	Amount to be Registered(1)	Proposed Maximum Offering Price per Share	Proposed Maximum Aggregate Offering Price	Amount of Registration Fee
Common Stock, par value \$0.001 per share 2013 Equity Incentive Plan	2,438,344 (2)(3)	\$37.88 (4)	\$92,364,470.72	\$10,732.76
Total	2,438,344		\$92,364,470.72	\$10,732.76

- (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), this Registration Statement shall also cover any additional shares of common stock of Portola Pharmaceuticals, Inc. (the Registrant) that become issuable under the 2013 Equity Incentive Plan (the 2013 Plan) set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of the Registrant's common stock.
- (2) Represents additional shares of the Registrant's common stock reserved for future issuance under the 2013 Plan by reason of the automatic increase provision of the 2013 Plan.
- (3) The number of shares reserved for issuance under the 2013 Plan will automatically increase on January 1st each year, starting on January 1, 2014 and continuing through January 1, 2023, by the lesser of (a) five percent (5%) of the total number of shares of the Registrant's common stock outstanding on December 31st of the immediately preceding calendar year and (b) a number determined by the Registrant's board of directors.
- (4) Estimated in accordance with Rule 457(h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of \$37.88, the average of the high and low prices of the Registrant's common stock as reported on The NASDAQ Global Select Market on February 26, 2015.

EXPLANATORY NOTE

Portola Pharmaceuticals, Inc. (the Registrant) is filing this Registration Statement on Form S-8 for the purpose of registering an additional 2,438,344 shares of its common stock, par value \$0.001 per share (the Common Stock), issuable to eligible persons under the 2013 Equity Incentive Plan, which Common Stock is in addition to the shares of Common Stock registered on the Registrant s Form S-8 filed on May 31, 2013 (File No. 333-188996) and Form S-8 filed on May 12, 2014 (File No. 333-195897).

PART II

ITEM 3. INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

The Registration Statement on Form S-8 (File No. 333-188996) filed by the Registrant with the Securities and Exchange Commission on May 31, 2013 is incorporated by reference into this Registration Statement.

The Registration Statement on Form S-8 (File No. 333-195897) filed by the Registrant with the Securities and Exchange Commission on May 12, 2014 is incorporated by reference into this Registration Statement.

All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

ITEM 8. EXHIBITS

Exhibit

Number	Description
5.1	Opinion of Cooley LLP.
23.1	Consent of Independent Registered Public Accounting Firm.
23.2	Consent of Cooley LLP (included in Exhibit 5.1).
24.1	Power of Attorney (included on the signature page of this Form S-8).

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of South San Francisco, State of California, on March 2, 2015.

PORTOLA PHARMACEUTICALS, INC.

By: /s/ Mardi C. Dier
 Mardi C. Dier
 Executive Vice President and Chief
 Financial Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints William Lis and Mardi C. Dier, and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ William Lis	Chief Executive Officer and Director	March 2, 2015
William Lis	<i>(Principal Executive Officer)</i>	
/s/ Mardi C. Dier	Executive Vice President and	March 2, 2015
Mardi C. Dier	Chief Financial Officer	
	<i>(Principal Financial and Accounting Officer)</i>	
/s/ Hollings C. Renton	Chairman of the Board of Directors	March 2, 2015
Hollings C. Renton		
/s/ Jeffrey W. Bird, M.D., Ph.D.	Director	March 2, 2015

Edgar Filing: PORTOLA PHARMACEUTICALS INC - Form S-8

Jeffrey W. Bird, M.D., Ph.D.

/s/ Laura A. Brege

Director

March 2, 2015

Laura A. Brege

Director

Dennis Fenton, Ph.D.

Director

Nicholas G. Galakatos, Ph.D.

/s/ Charles J. Homcy, M.D.

Director

March 2, 2015

Charles J. Homcy, M.D.

/s/ John H. Johnson

Director

March 2, 2015

John H. Johnson

/s/ H. Ward Wolff

Director

March 2, 2015

H. Ward Wolff

EXHIBIT INDEX

Exhibit

Number	Description
5.1	Opinion of Cooley LLP.
23.1	Consent of Independent Registered Public Accounting Firm.
23.2	Consent of Cooley LLP (included in Exhibit 5.1).
24.1	Power of Attorney (included on the signature page of this Form S-8).